Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of ...

Explore the booming Myasthenia Gravis market in the 7MM with projections to 2034. Current therapies include prednisone and pyridostigmine, with monoclonal antibodies for aggressive cases. Valued at $6 ...

The landscape of gMG treatment is rapidly evolving, said John Morren, MD, of the Cleveland Clinic. The traditional approach ...

How One Woman Turned a Life-Altering Diagnosis Into a Source of Hope, Strength, and Support for Chronic Illness Warriors CA, UNITED ST ...

Imagine having to consider your health and its limitations every single day. Often, we take our health for granted, but unfortunately for many across Europe, the Middle East and Africa (EMEA), the ...

Myasthenia gravis (MG) in children and adolescents to age 18 -- juvenile MG -- includes clinically significant developmental issues like puberty that are not present in adult disease. Despite this ...

Mirima Freimer, MD, delves into potential reasons behind the longer-term efficacy of zilucoplan and also speaks to the treatment’s safety profile.

Microsoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing will ...

COMMENT: It’s not just on maternity wards where Black women are denied pain relief or more likely to suffer poorer outcomes – ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

Vor Biopharma Inc. (NASDAQ:VOR) is one of the hot penny stocks to invest in now. In a report released on June 30, ...

Vor Biopharma pivots to telitacicept with $175M funding, eyeing multi-billion potential. Risks include dilution, regulatory hurdles, and operational challenges. Read more on VOR.